Champions Oncology Inc Aktie
Deine Einschätzung
Champions Oncology Inc Aktie
Was spricht für und gegen Champions Oncology Inc in den nächsten Jahren?
Pro
Kontra
Rendite von Champions Oncology Inc im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Champions Oncology Inc | 1,66 % | -0,41 % | 0,82 % | -35,95 % | -15,52 % | 32,43 % | -48,42 % |
| Heron Therapeutics Inc. | -0,22 % | -3,74 % | -32,09 % | -64,61 % | -37,70 % | -50,32 % | -95,08 % |
| Evolus Inc | -6,99 % | -4,95 % | -5,98 % | -68,83 % | -36,51 % | -55,06 % | -67,66 % |
| Sangamo Therapeutics Inc. | 18,00 % | -12,66 % | -29,34 % | -56,63 % | -25,24 % | -83,84 % | -97,49 % |
Kommentare
News
Die U.S. Polo Assn. unterstützt die Division I National Intercollegiate Championship und präsentiert damit die Zukunft des Polosports
Die DI Women's and Men's Finals werden in der Sendung „Breakaway: Polo in College“ auf ESPN zu sehen sein
WEST PALM BEACH, FLORIDA / ACCESS Newswire / 2. April 2026 / U.S. Polo Assn., die
U.S. Polo Assn. Supports Division I National Intercollegiate Championship, Showcasing the Future of the Sport of Polo
DI Women's and Men's Finals to be Featured in ‘Breakaway: Polo in College' on ESPN
WEST PALM BEACH, FLA. / ACCESS Newswire / April 2, 2026 / U.S. Polo Assn., the official sports brand of
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D
HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology,



